Overall ? The mission of the San Diego Center for AIDS Research (SD CFAR) is to find a cure for HIV for those already infected, and to prevent HIV transmission to those not infected. Our Center?s research priorities are aligned with the NIH Office of AID Research priorities and include: optimizing HIV care, alleviating HIV health disparities and advancing scientific discovery for HIV cure and vaccine efforts.
The specific aims of the SD CFAR are to: 1. Foster innovative HIV research by providing the foundation and framework for highly productive collaborations across disciplines, investigators, member institutions, and the HIV community. 2. Capitalize on our community engagement and international expertise to develop sustainable research programs locally and in targeted low and middle income countries highly impacted by HIV. 3. Provide Training, Inspiration, Mentoring, and Expert guidance (TIME) to local and international investigators across career stages. 4. Thoughtfully plan our Center?s growth and flexibility to adapt to an ever evolving research environment. Structure: The SD CFAR is multi-institutional, with members at La Jolla Institute of Allergy and Immunology (LJI), Sanford Burnham Prebys Medical Discovery Institute (SBP), The Scripps Research Institute (TSRI), and University of California San Diego (UCSD). The Center is co-directed by members of our Operations Team including Drs. Davey Smith (contact PI), Douglas Richman, Robert Schooley, and Bruce Torbett. Our CFAR is comprised of ten Cores and one Scientific Working Group. One of these Cores, the Disparities Core, is completely funded by the California HIV Research Program, but remains ingrained as a standalone Core in our Center. We continue to be guided by our External Advisory and Executive Committees, as well as our Co- Directors, Core Directors, Scientific Working Groups and our membership. Progress: Since our renewal in 2012, these efforts have yielded a productive, enthusiastic and growing group of investigators. As the synergy among our investigators and member institutions increases, we have identified the need to expand our infrastructure to address new opportunities. This success has culminated in our move from a Tier 2 to Tier 3 CFAR.

Public Health Relevance

Overall - The SD CFAR supports basic, clinical, behavioral and translational research programs across our member institutions. These activities add considerable value to NIH funded HIV research. In addition to our active, productive and groundbreaking research, we have a remarkable program for fostering the development of emerging investigators, including scientists new to HIV research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-25
Application #
9674207
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Wong, Elaine Wai-Ken
Project Start
1997-04-01
Project End
2023-03-31
Budget Start
2019-04-01
Budget End
2020-03-31
Support Year
25
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of California, San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Naticchia, Matthew R; Laubach, Logan K; Tota, Ember M et al. (2018) Embryonic Stem Cell Engineering with a Glycomimetic FGF2/BMP4 Co-Receptor Drives Mesodermal Differentiation in a Three-Dimensional Culture. ACS Chem Biol 13:2880-2887
Blumenthal, Jill; Jain, Sonia; Mulvihill, Evan et al. (2018) Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr :
Kardava, Lela; Sohn, Haewon; Youn, Christine et al. (2018) IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol 19:1001-1012
Wagner, Karla D; Syvertsen, Jennifer L; Verdugo, Silvia R et al. (2018) A mixed methods study of the social support networks of female sex workers and their primary noncommercial male partners in Tijuana, Mexico. J Mix Methods Res 12:437-457
Bastos, Francisco I; Bastos, Leonardo Soares; Coutinho, Carolina et al. (2018) HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine (Baltimore) 97:S16-S24
Cepeda, Javier A; Eritsyan, Ksenia; Vickerman, Peter et al. (2018) Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5:e578-e587
Namazi, Golnaz; Fajnzylber, Jesse M; Aga, Evgenia et al. (2018) The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis 218:1954-1963
Lada, Steven M; Huang, Karissa; VanBelzen, D Jake et al. (2018) Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56:
Huang, Mia L; Michalak, Austen L; Fisher, Christopher J et al. (2018) Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells 36:45-54
Skaathun, Britt; Voisin, Dexter R; Cornwell, Benjamin et al. (2018) A Longitudinal Examination of Factors Associated with Network Bridging Among YMSM: Implications for HIV Prevention. AIDS Behav :

Showing the most recent 10 out of 921 publications